Zobrazeno 1 - 10
of 167
pro vyhledávání: ''
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Autor:
J. S. Haw, Michael Mauer, Janet B. McGill, Jill P. Crandall, Bruce A. Perkins, Ruth S. Weinstock, Katherine R. Tuttle, Afshin Parsa, Tom Elliott, Peter Rossing, Amy B. Karger, Amisha Wallia, Cathie Spino, Mark E. Molitch, I. H. de Boer, Maryam Afkarian, David Z.I. Cherney, Sylvia E. Rosas, Irl B. Hirsch, Sarit Polsky, Allison B. Goldfine, Andrzej T. Galecki, Guillermo E. Umpierrez, Ronald J. Sigal, Marlon Pragnell, Ildiko Lingvay, M. L. Caramori, Rodica Pop-Busui, Ronnie Aronson, William N. Robiner, Chun Yi Wu, David M. Maahs, Peter A. Senior, Alessandro Doria
Publikováno v:
N Engl J Med
BACKGROUND: Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes a
Autor:
Axel Grothey, Sara Lonardi, Victor Sandor, Neeltje Steeghs, Rona Yaeger, Elena Elez, Yong Sang Hong, Harpreet Wasan, Christina Guo, Jan H.M. Schellens, Tae Won Kim, Eric Van Cutsem, Ashwin Gollerkeri, Tormod Kyrre Guren, Fotios Loupakis, Line Schmidt Tarpgaard, Kati Maharry, Jayesh Desai, Lisa Anderson, Sergey Orlov, Aitana Calvo Ferrándiz, Jeroen Dekervel, Michael Braun, Per Pfeiffer, Asha Krishnan, Pilar García-Alfonso, Michael D Pickard, Scott Kopetz, Janna Christy-Bittel, Hendrik Tobias Arkenau, Takayuki Yoshino, Fortunato Ciardiello, Christopher Hunt Keir, Van Morris, Josep Tabernero
Publikováno v:
Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075
BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of path
Autor:
Kalehiwot M Wubie, Marcus V. G. Lacerda, Françoise Brand, Kim Fletcher, Alemseged Abdissa, Nillawan Buathong, Elizabeth Hardaker, Harald Noedl, Victoria M Rousell, Ermias Diro, Jörg-Peter Kleim, Monica R. F. Costa, Brian Angus, John J Breton, Alejandro Llanos-Cuentas, Lynda Kellam, Reginaldo Z Mia, Marcelo A M Brito, Martin Casapia, Hans-Peter Beck, Fe Espino, Raul Chuquiyauri, Wuelton Marcelo Monteiro, Rezika Mohammed, Donna D Clover, Fernando Val, Sisay Getie, Justin A. Green, Dhelio Batista Pereira, Daniel Yilma, Stephan Duparc, Mauro Shugiro Tada, Cherinet Abebe, Ahmed Zeynudin, Siôn W. Jones, Khadeeja Mohamed, David L. Saunders, Cletus O Ugwuegbulam, Gavin C. K. W. Koh, Chanthap Lon, Srivicha Krudsood
Publikováno v:
The New England Journal of Medicine
Background Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-a
Autor:
Anne Armstrong, Seock-Ah Im, Nadine Tung, C. Goessl, Suzette Delaloge, Elżbieta Senkus, Wei Li, Mark E. Robson, Susan M. Domchek, Pierfranco Conte, Wenting Wu, Norikazu Masuda, Binghe Xu, Sarah Runswick
Publikováno v:
New England Journal of Medicine. 377:523-533
Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.We conducted a randomized, open-label, phase 3 trial in which ola
Autor:
Fizazi, Karim, Tran, Namphuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez Antolin, Alfredo, Alekseev, Boris Y., Ãzgã¼roglu, Mustafa, Dingwei, Ye, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary B., Chi, Korbenfeld E, Kim N., Metrebian, S, Kaen, L, Staneloni, E, Batagelj, E, Tan, H, Hovey, E, Woo, H, Frydenberg, M, Chua, W, D’Hondt, L, Evaraert, E, Verschaeve, V, Wynendaele, W, Schrijvers, D, Waltregny, D, Whenham, N, Demey, W, Franke, F, Panhoca, R, Damião, R, Zucca, L, Da Rosa, V, Reis, R, Scalabrini, A, Nahas, W, Girotto, G, Nogueira, A, Gomes, A, Coradazzi, A, Kurteva, G, Siemens, R, Gingerich, J, Fleshner, N, Fradet, Y, Morgan, S, North, S, Saad, F, Shayegan, B, Zalewski, P, Pinochet, R, Orellana, N, Ding, Q, Ye, Z, Xie, L, Du, C, Chen, Z, Huang, Y, Sun, Z, Li, H, Jin, J, Li, C, Wan, B, Tian, Y, Zhou, F, Xie, K, Yao, X, Qiu, M, Zou, Q, Na, Y, Sun, Y, Xue, B, Ma, L, Martinez, C, Salazar, M, Larios, C, Solano, S, Pavlik, I, Brodak, M, Hora, M, Büchler, T, Borre, M, Johansen, J, Mejlholm, I, Poulsen, M, Wittendorf, He, Tammela, T, Vaarala, M, Theodore, C, Staudacher, L, Villers, A, Laplaige, P, Suttman, H, Steuber, T, Natale, S, Jones, R, Tran, A, Mazhar, D, Mills, J, Nyirady, P, Salamon, C, Torzsok, F, Feher, J, Géczi, L, Lakatos, A, Keizman, D, Sella, A, Frank, S, Peer, A, Rosenbaum, E, Berger, R, Mermershtain, W, Carteni, G, Tonini, G, De Giorgi, U, Facchini, G, Berruti, Alfredo, Bracarda, S, Basso, U, Galli, L, Tortora, G, Alietta, M, Fukasawa, S, Suzuki, H, Hasumi, H, Tsuchiya, T, Uemura, H, Kanayama, H, Hashine, K, Sato, F, Matsumoto, H, Oya, M, Lee, Jl, Park, S, Keam, B, Yun, H, Kim, Y, Kang, B, Lee, K, Kim, C, Saad, M, Sundram, M, Calvo, D, Moreno, R, Rodriquez, J, Hernandez, C, van den Berg, H, De La Rosett, J, Van Moorse, R, Hunting, J, Hendriks, M, Kueppers, F, Gilling, P, Beaven, A, Holmes, M, Jassem, J, Oszukowska, E, Niezabitowski, J, Jaxa Larecka, D, Chwalinski, M, Swiniarski, P, Silva, C, Conceicãoa, P, Fraga, A, Mauricio, J, Rodrigues, T, Pinheiro, L, Lima, E, Palma Dos Reis, J, Volovat, C, Jinga, V, Harza, M, Alyasova, A, Budnik, N, Bychkov, Y, Izmaylov, A, Khvorosten, D, Matveev, V, Novsov, A, Vladimirov, V, Tevs, D, Sheveleva, L, Bulanov, A, Semenov, A, Fadeeva, N, Kulikov, E, Emelyanov, S, Karyakin, O, Shirinkin, V, Shkolnik, M, Lykov, A, Skopin, P, Kopyltsov, E, Mincik, I, Mir, O, Kliment, J, Mikurcik, E, Gajdos, M, Milichovsky, I, Malan, J, Bahlmann, J, Moshokoa, E, Madlala, T, Coetzee, L, Ribal, M, Miñana, B, Martinez Breijo, S, Carballido, J, Olmos, D, Requena, M, Morote, J, Damber, Je, Haggman, M, Nyman, C, Ljungberg, B, Bjartell, A, Ozen, H, Beduk, Y, Sozen, S, Cetinkaya, M, Ozyurt, M, Tansug, Z, Mungan, A, Tanidir, Y, Toktas, M, Hotko, E, Stus, V, Lyulko, O, Vinnyk, Y, Shparyk, Y, Sakalo, V, Bondarenko, I, Paramonov, V, Khareba, G, Hodos, V.
Publikováno v:
The New England journal of medicine, Vol. 377, no. 4, p. 352-360 (2017)
Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivatio
Autor:
Parameswaran, Nair, Sally, Wenzel, Klaus F, Rabe, Arnaud, Bourdin, Njira L, Lugogo, Piotr, Kuna, Peter, Barker, Stephanie, Sproule, Sandhia, Ponnarambil, Mitchell, Goldman, Manuel, Villareal
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2017, 376 (25), pp.2448--2458. ⟨10.1056/NEJMoa1703501⟩
New England Journal of Medicine, Massachusetts Medical Society, 2017, 376 (25), pp.2448--2458. ⟨10.1056/NEJMoa1703501⟩
Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the inciden
Autor:
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar‑or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H. -P., Hemmer, B., Lublin, F., Rammohan, K. W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., Garren, H., Mairon, N., Chin, P., Wolinsky, J. S., Uccelli, A, for the ORATORIO Clinical Investigators
Publikováno v:
New England Journal of Medicine, 376(3), 209-220. MASSACHUSETTS MEDICAL SOCIETY
Scientia
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2017, 376 (3), pp.209-220. ⟨10.1056/NEJMoa1606468⟩
Scientia
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2017, 376 (3), pp.209-220. ⟨10.1056/NEJMoa1606468⟩
Ocrelizumab; Placebo; Multiple sclerosis Ocrelizumab; Placebo; Esclerosi múltiple Ocrelizumab; Placebo; Esclerosis múltiple BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could
Autor:
Barbara Sleight, M. Luisa Paccagnella, Wendy Stock, Erik Vandendries, Susan O'Brien, Matthias Stelljes, Nicola Gökbuget, Daniel J. DeAngelo, Tao Wang, Giovanni Martinelli, Kongming Wang, Hagop M. Kantarjian, Michaela Liedtke, Anjali S. Advani
Publikováno v:
New England Journal of Medicine. 375:740-753
The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory a
Autor:
Iván D. Vélez, Wuelton Marcelo Monteiro, Lindsay Kendall, Siôn W. Jones, Victoria M Rousell, Raul Chuquiyauri, Chayadol S Namaik-Larp, Justin A. Green, Marcus V. G. Lacerda, Graham Craig, Marcelo A M Brito, François Nosten, Gavin C. K. W. Koh, Fernando Val, Cindy S. Chu, Elizabeth Hardaker, Ratchadaporn Papwijitsil, Tran Tinh Hien, Sandra Aruachan, Donna D Clover, Martin Casapia, Alejandro Llanos-Cuentas, Germana Bancone, Brian Angus, Viviana M Wilches, Maria F Villegas, Chau H Nguyen, John J Breton, Stephan Duparc, Monica R. F. Costa, Khadeeja Mohamed
Publikováno v:
The New England Journal of Medicine
BACKGROUND Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed “radical cure.” METHODS We performed a phase 3, prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1301e8e7c12abf617a49c556a3c81afc
https://hdl.handle.net/20.500.12866/6917
https://hdl.handle.net/20.500.12866/6917